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A corrigendum on
Safety Profiles of Tripterygium wilfordiiHook F: A Systematic Review and Meta-Analysis
by Zhang, C., Sun, P.-P., Guo, H.-T., Liu, Y., Li, J., He, X.-J., et al. (2016). Front. Pharmacol. 7:402.
doi: 10.3389/fphar.2016.00402
In the original article, there was an error. “Aspirin” was referred to instead of “TwHF.”
A correction has been made to the last sentence of the Results section in the abstract:
We screened 4137 abstracts for eligibility and included 594 studies in the analysis. The overall
incidence of AEs was 26.7% (95% CI 24.8%, 28.8%) in 23,256 TwHF users. The estimates did
vary markedly when stratified by specific study types. The incidence of gastrointestinal symptoms,
adverse reproductive outcomes, adverse skin reactions, hematologic events and cardiovascular
events were 13.3% (95% CI 11.9%, 14.9%), 11.7% (95% CI 10.3%, 13.3%), 7.8% (95% CI 6.3–9.5%),
6.5% (95% CI 5.7–7.4 %) and 4.9% (95% CI 1.6 %, 14.3 %), respectively. The prevalence of irregular
menstruation (IM)was increased in patients taking TwHF comparedwith those given control (odds
ratio [OR] 4.65, 95% CI 3.08 to 7.03). TwHF use has lower risk of weight gain (OR 0.12 [95% CI
0.04 to 0.39]) and hair loss (OR 0.37 [95% CI 0.18 to 0.78]). Furthermore, long-term TwHF use
(>6 months) has a higher AEs incidence (31.0% [95% CI 24.5%–38.5%]).
The authors apologize for this error and state that this does not change the scientific conclusions
of the article in any way.
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